@article{23135cef5b8c4212942381835b0f7fea,
title = "Effect of Infant RSV Infection on Memory T Cell Responses at Age 2-3 Years",
abstract = "Background: It is unknown whether RSV infection in infancy alters subsequent RSV immune responses. Methods: In a nested cohort of healthy, term children, peripheral blood mononuclear cells (PBMCs) were collected at ages 2-3 years to examine RSV memory T cell responses among children previously RSV infected during infancy (first year of life) compared to those RSV-uninfected during infancy. The presence vs. absence of infant RSV infection was determined through a combination of RSV molecular and serologic testing. Memory responses were measured in RSV stimulated PBMCs. Results: Compared to children not infected with RSV during the first year of life, children infected with RSV during infancy had lower memory T cell responses at ages 2-3 years to in vitro stimulation with RSV for most tested type-1 and type-17 markers for a number of memory T cell subsets. Conclusions: RSV infection in infancy has long-term effects on memory T cell responses. This is the first study to show the potential for RSV infection in infancy to have long-term effects on the immune memory irrespective of the severity of the infection. Our results suggest a possible mechanism through which infant RSV infection may result in greater risk of subsequent childhood respiratory viral morbidity, findings also relevant to vaccine development.",
keywords = "RSV (respiratory syncytial virus), asthma, children, epidemiology, infants, memory immune response, peripheral blood mononuclear cells",
author = "Tatiana Chirkova and Christian Rosas-Salazar and Tebeb Gebretsadik and Jadhao, {Samadhan J.} and Chappell, {James D.} and Peebles, {R. Stokes} and Dupont, {William D.} and Newcomb, {Dawn C.} and Sergejs Berdnikovs and Gergen, {Peter J.} and Hartert, {Tina V.} and Anderson, {Larry J.}",
note = "Funding Information: We would like to thank Donald H. Arnold, Alyssa Bednarek, Andrew Bender, Steven M. Brunwasser, Sandra Alvarez-Macias, Teresa M. Chipps, Alexandra S. Connolly, Kaitlin M. Costello, Suman R. Das, Marian T. Dorst, Roxanne Filardo-Collins, Rebecca Gammell, Kayla Goodman, Karin Han, Anca M. Ifrim, Ashudee Kirk, Emma K. Larkin, Jessica Levine, Zhouwen Liu, Christian E. Lynch, Megan McCollum, Rendie McHenry, Kelsie McMurtry, Patricia A. Minton, Paul E. Moore, Barron L. Patterson, Fernando P. Polack, Sara Reiss, Theresa Rogers, Patty Russell, Meghan H. Shilts, Brittney M. Snyder, Stephanie Steen, ZhengZheng Tang, Kedir N. Turi, Shanda Vereen, Madison Wagener, Kimberly B. Woodward, and Pingsheng Wu from the Center for Asthma Research at Vanderbilt University Medical Center; the Pediatric/Winship Flow Cytometry Core of the Department of Pediatrics at Emory University School of Medicine; Mackenzie E. Coden and Brian M. Jeong from Northwestern University Feinberg School of Medicine; Nathan Dyjack and Jamie L. Everman from National Jewish Health; Joy Laurienzo Panza from the National Institute of Allergy and Infectious Diseases; and all the INSPIRE participants and their families for their involvement in and dedication to this study. Funding Information: This work was supported in whole or in part with funds from the National Institute of Allergy and Infectious Diseases (under award numbers U19AI095227 and K24AI77930); the Vanderbilt Institute for Clinical and Translational Research (grant support from the National Center for Advancing Translational Sciences under award number UL1TR000445); the National Heart, Lung, and Blood Institute (under award number K23HL148638); the Parker B. Francis Fellowship Program; and the Department of Pediatrics at Vanderbilt University Medical Center (grant support from the Eunice Kennedy Shriver National Institute of Child Health and Human Development under award number K12HD087023). Funding Information: LA has served on respiratory syncytial virus (RSV) vaccine advisory boards for Bavarian Nordic, Novavax, Daiichi-Sankyo, ClearPath Vaccines Company, ADVI, and Pfizer. Through Emory University, his laboratory currently receives funding from Pfizer for surveillance studies of RSV infection in adults, from Advaccine Biopharmacueticals Suzhou Co., Ltd. For serologic studies of RSV vaccine recipients, and from Sciogen for animal studies on RSV vaccines. He is a co-inventor on several Centers for Disease Control and Prevention patents on the RSV G protein and its CX3C chemokine motif relative to immune therapy and vaccine development. He is also co-inventor on a patent filing for the use of RSV platform virus-like particles with the F and G proteins for vaccines. TH has served on RSV vaccine advisory boards for Sanofi-Pasteur and Pfizer. Publisher Copyright: Copyright {\textcopyright} 2022 Chirkova, Rosas-Salazar, Gebretsadik, Jadhao, Chappell, Peebles, Dupont, Newcomb, Berdnikovs, Gergen, Hartert and Anderson.",
year = "2022",
month = mar,
day = "17",
doi = "10.3389/fimmu.2022.826666",
language = "English (US)",
volume = "13",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",
}
